Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France)
Author(s) -
D Lévy-Brühl,
A Perrocheau,
Mauricio M. Mora,
MuhamedKheir Taha,
S Dromell-Chabrier
Publication year - 2002
Publication title -
eurosurveillance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.766
H-Index - 104
eISSN - 1560-7917
pISSN - 1025-496X
DOI - 10.2807/esm.07.05.00368-en
Subject(s) - medicine , meningococcal disease , incidence (geometry) , vaccination , purpura fulminans , case fatality rate , pediatrics , emergency department , epidemiology , disease , neisseria meningitidis , immunology , surgery , physics , psychiatry , biology , bacteria , optics , genetics
In the department of Puy-de-Dôme, France, 17 cases of invasive meningococcal disease C were notified between March 2001 and the first week of 2002. Among the 15 confirmed cases, 11 (73%) were serogroup C, 2 (13%) serogroup B, and 2 could not be identified. The rapid increase in the number of cases in a period of low endemicity for the rest of the country and the severity of the disease (case fatality ratio 27%, purpura fulminans 64%) led the health authorities to initiate a vaccination campaign targeting children and young adults from 2 months up to 20 years living in a limited area of the department. Around 80 000 people were immunised between 16/01/02 and 09/02/02. More than half of the 1390 immediate side effects were headache and dizziness. As of mid-March, no further case of meningococcal disease has been notified since 6 January.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom